We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 13, 2017

Veliparib Alone or With Carboplatin for BRCA-Associated Metastatic Breast Cancer

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Efficacy of the PARP Inhibitor Veliparib With Carboplatin or as a Single Agent in Patients With Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer
Clin. Cancer Res 2017 Mar 29;[EPub Ahead of Print], G Somlo, P Frankel, B Arun, CX Ma, A Garcia, T Cigler, L Cream, H Harvey, JA Sparano, R Nanda, HK Chew, T Moynihan, MP Goetz, L Vahdat, JH Beumer, A Hurria, J Mortimer, R Piekarz, S Sand, J Herzog, LR Van Tongeren, K Ferry-Galow, A Chen, C Ruel, E Newman, DR Gandara, JN Weitzel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading